Siemens' DPC (Diagnostic Products Corporation) buy gets German OK:
This article was originally published in Clinica
Siemens' proposed acquisition of Los Angeles, California-based immunodiagnostics company Diagnostic Products Corporation (DPC) has received clearance from German antitrust authorities. The news comes shy of a week after the US Federal Trade Commission gave the go-ahead to the $1.86bn transaction (see Clinica No 1211, p 14). The companies still require shareholder approval before closing the acquisition.
You may also be interested in...
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.